Point72 Europe’s Coherus Oncology CHRS Stock Holding History

Point72 Europe’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,980	Closed	-$6.59K	–	171
2023 Q4	$6.59K	Buy	+1,980	New	+$5.3K	﹤0.01%	415

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 Europe's CHRS Position: Q1 2024 in Review

Point72 Europe sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 1,980 shares — an estimated $6.59K sold.

Point72 Europe first reported a position in CHRS in Q4 2023 and held it in 1 quarter. The position peaked at $6.59K in Q4 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

Point72 Europe reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
Point72 Europe sold 1,980 Coherus Oncology shares in Q1 2024, an estimated $6.59K.
Point72 Europe first reported a position in Coherus Oncology in Q4 2023 and held it in 1 quarter.
Point72 Europe's Coherus Oncology position peaked at $6.59K in Q4 2023.
137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Point72 Europe's 13F filing for Q1 2024, filed 15 May 2024.